Senores Pharmaceuticals’ Performance Analyzed

Senores Pharmaceuticals had a really strong quarter, showing significant growth in both sales and profits. In the period ending December 2025, the company’s sales jumped by 60.02% to a total of Rs 164.85 crore. This is a big increase from the Rs 103.02 crore they made in the previous quarter.

Key Points

• Sales increased dramatically – 60.02% to Rs 164.85 crore.
• Net profit soared by 84.28% to Rs 31.66 crore.
• Profit margins improved, reaching 32.76% in Q4 2025.
• Profit Before Tax (PBDT) rose by 112% to Rs 52.46 crore.
• Profit After Tax (PBT) climbed 118% to Rs 44.60 crore.
• Net Profit (NP) increased by 84.28% to Rs 31.66 crore.

Financial Highlights – December 2025

The company’s net profit also increased significantly, rising by 84.28% to Rs 31.66 crore. This was a substantial improvement compared to the Rs 17.18 crore reported in the prior quarter.

Profitability Metrics

Key profitability numbers show a positive trend. The company achieved a profit margin of 32.76% during the December 2025 quarter, compared to 24.94% in the previous quarter.

Profit Before Tax (PBDT) reached Rs 52.46 crore, an increase of 112%. Similarly, Profit After Tax (PBT) jumped to Rs 44.60 crore, marking a 118% rise.

Finally, the company’s Net Profit (NP) reached Rs 31.66 crore, representing an 84.28% increase.

“Strong financial results demonstrate Senores Pharmaceuticals’ trajectory for continued growth and market leadership.